PharmaCyte Biotech (PMCB)
Develops CypCaps, a cell-encapsulation pancreatic cancer therapy candidate.
Something off on this page? Send us feedback.
Develops CypCaps, an encapsulated-cell candidate designed to activate a cancer prodrug near pancreatic tumors. With no approved products or revenue, operations depend on outsourced research and a sole-source manufacturing partner while the development program remains under FDA clinical hold.
Develops CypCaps, a Cell-in-a-Box-based candidate for locally advanced, inoperable, non-metastatic pancreatic cancer. The cellulose microcapsules are designed to hold genetically engineered cells near a tumor, where they would locally convert the separately administered prodrug ifosfamide into its active form. The company has no approved product or product-sales revenue and reports a research-and-development segment focused on cellular cancer therapies.
Operates from Las Vegas through an outsourced network that includes SG Austria, Austrianova Singapore, and a manufacturing facility in Bangkok. Development spending is curtailed while the board reviews the program and its relationship with SG Austria. Progress depends on lifting the FDA clinical hold, completing the remaining product, delivery-device, and compatibility work, and Austrianova's sole-source encapsulation and manufacturing capabilities.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $37.1M · Total debt $0 · Total assets $46.8M · Shareholders' equity $33.3M
- Revenue
- $0
- Operating income
- −$2.5M
- Net income
- −$4.4M
No dividends on record.
| Institutions33 holders · as of Mar 31, 2026 | 9.01% | 967.3K shares | |
| Insiders5 holders · as of Jan 7, 2026 | 6.45% | 692.9K shares | |
| Otherremainder | 84.54% | 9.08M shares |
10.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Joshua SilvermanInsiderdirector, officer: CEO and President | 3.88% | 416,250 | Form 4filed Jan 7, 2026 ↗ |
Citadel Advisors LLCInstitution | 3.35% | 359,547 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.82% | 195,660 | 13Fas of Mar 31, 2026 |
Jonathan SchechterInsiderdirector | 1.79% | 192,500 | Form 4filed Jan 7, 2026 ↗ |
Renaissance Technologies LLCInstitution | 0.53% | 56,500 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 5, 2026 | Jonathan Schechter | director | +20,000 | $0.7776 |
| Jan 6, 2026 | Jonathan Schechter | director | +20,000 | $0.7904 |
| Jan 7, 2026 | Jonathan Schechter | director | +20,000 | $0.8436 |
| Jan 5, 2026 | Joshua Silverman | director, officer: CEO and President | +30,000 | $0.7831 |
| Jan 6, 2026 | Joshua Silverman | director, officer: CEO and President | +30,000 | $0.7889 |
- Novocure
Approved TTFields add-on for locally advanced pancreatic cancer.
- RenovoRx
Closest local-delivery Phase III alternative for locally advanced disease.
- Bristol-Myers Squibb
Abraxane anchors an incumbent pancreatic-chemotherapy regimen.
- Revolution Medicines
Late-stage RAS-targeted therapy for pancreatic ductal adenocarcinoma.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech | $0.4808 | −1.50% | $5.2M | — | — | — | — |
| Novocure | $18.30 | +2.61% | $2.08B | — | — | 3.0 | +15.6% |
| RenovoRx | $2.67 | +6.37% | $113.5M | — | — | 57.5 | +115.4% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Revolution Medicines | $210.42 | +0.57% | $44.48B | — | — | — | — |
| Median | 14.9 | 10.6 | 3.0 | +15.6% |